This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Dec;6(12):1264.

doi: 10.1016/j.oret.2022.08.021.

Re: Singh et al: Efficacy outcomes of brolucizumab versus aflibercept in neovascular age-related macular degeneration patients with early residual fluid (Ophthalmol Retina. 2022;6:377-386)

Akio Oishi¹, Yuki Maekawa², Takashi Kitaoka²

Affiliations

Affiliations

¹ Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. Electronic address: akio.oishi@nagasaki-u.ac.jp.
² Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

PMID: 36462790
DOI: 10.1016/j.oret.2022.08.021

Comment

Re: Singh et al: Efficacy outcomes of brolucizumab versus aflibercept in neovascular age-related macular degeneration patients with early residual fluid (Ophthalmol Retina. 2022;6:377-386)

Akio Oishi et al. Ophthalmol Retina. 2022 Dec.

. 2022 Dec;6(12):1264.

doi: 10.1016/j.oret.2022.08.021.

Authors

Akio Oishi¹, Yuki Maekawa², Takashi Kitaoka²

Affiliations

¹ Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. Electronic address: akio.oishi@nagasaki-u.ac.jp.
² Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

PMID: 36462790
DOI: 10.1016/j.oret.2022.08.021

No abstract available

PubMed Disclaimer

Comment on

Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
Singh RP, Jhaveri C, Wykoff CC, Gale RP, Staurenghi G, Iida T, Koh A, B G, Gedif K, Singer M. Singh RP, et al. Ophthalmol Retina. 2022 May;6(5):377-386. doi: 10.1016/j.oret.2021.12.014. Epub 2021 Dec 27. Ophthalmol Retina. 2022. PMID: 34968756 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information